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UNRELATED STEM CELL TRANSPLANTATION (SCT) FOR FANCONI ANE-
MIA(FA) USING CYCLOPHOSPHAMIDE(CY)  FLUDARABINE(FLU) 
THYMOGLOBULINE(THYMO): CONSECUTIVE ANALYSIS OF 20 PA-
TIENTS TREATED AT THE SAME INSTITUITION
Bonﬁm, C.M.S.; Bitencourt, M.A.; Setubal, D.C.; Funke, V.A.M.;
Ruiz, J.; Aduan, M.; Dourado, D.; de Medeiros, C.R.; Zanis-Neto, J.;
Pasquini, R. Bone Marrow Transplantation Service, Hospital de Clinicas
da UFPR, Curitiba, PR, Brazil.
Background: From 1983 until September 2004, 147 patients
received a SCT for FA in our BMT center and most of them were
in aplastic phase. In this study we selected 20 consecutive patients
who received an unrelated SCT for this disease using the same
preparative regimen. Patients and Methods: Period: 02/2000 to
09/2004; median age: 8 years (range, 4–14 years); sex: 13 females
and 7 males; median disease duration, 36 month (range, 7–67
months); previous transfusions: 1–65 UI(median, 12 UI); aplastic
phase: 20 patients; stem cell source: bone marrow (BM), 6 patients,
cord blood (CB), 14 patients; HLA disparities in 12 patients;
preparative regimen: CY 60mg/kg  FLU125 mg/m2  THY-
MO(rabbit) 4 mg/kg; GVHD prophylaxis: cyclosporine (Csa) 
MTX, 6 patients (BM) or Csa  steroids, 14 patients(CB).
All patients received prophylactic antibiotics according to com-
mon practice. Results: Eleven patients (55%) are alive and well
55–566 days after transplant (M:169d). Median time to reach
PMN 500/l was 23 days and that to reach platelets 20.000/l
was 25 days after transplantation. Seventeen patients were evalu-
able for engraftment (3 patients died before day 28), and 14
patients achieved complete hematologic recovery. Three pa-
tients had only neutrophil engraftment, and they all died early
after transplantation (on day 32, 34, and 58) due to infec-
tion complications. Nine patients died in the entire cohort be-
tween day 7 and 120 (median, 34 days), and in 8 patients
infection was the main cause of death. Acute GVHD grade II-IV
developed in 5 of 17 evaluable patients; chronic GVHD, in 1 of 10
evaluable patients. Mucositis grade III-IV occurred in 9 patients.
Due to delayed immune reconstitution, EBV lymphoproliferative
disease occurred in 3 patients, and in 1 of them it was the main
cause of death. Two patients treated with rituximab are alive and
well 6 and 10 months after EBV infection. There was no signiﬁcant
difference in survival for patients receiving BM or CB (67% vs
50%; P  .52). Patients receiving BM had a higher incidence of
mucositis grade III-IV (83%) compared with CB (29%). Acute
GVHD was the same in both groups and we did not observe
chronic GVHD in patients receiving BM. Conclusions: The use
of CY  FLU  THYMO as a preparative regimen in patients
with FA provided rapid and sustained engraftment for most pa-
tients. However, transplantation-related mortality is still very high,
and opportunistic infections occurring in the ﬁrst 100 days remain
the major causes of morbidity and mortality in this group of
patients.
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FACTORS INFLUENCING THE SUCCESS OF UNRELATED STEM CELL
DONOR (URD) SEARCH
Hong, S.L.W.1; Chitphakdithai, P.1; Dodson, K.L.1; Matlack, M.E.1;
Coppo, P.A.1; Weisdorf, D.J.2; Confer, D.L.1; Karanes, C.1 1. National
Marrow Donor Program, Minneapolis, MN; 2. Center for International
Blood & Marrow Transplant Research, Minneapolis, MN.
The NMDP retrospectively evaluated 2543 URD search pro-
cesses initiated between January 1, 2003 and June 30, 2003 in 3
groups of domestic transplant centers (TCs): 13 large research TCs
(RTCs), 25 growing TCs (GTCs), and 76 smaller TCs (STCs).
Each search was followed for 6 months. The number of patients
and donors at each stage, length of time between search stages,
search cancellations, level of HLA matching, the number of donors
requested at ﬁrst activation and donor availability were analyzed.
GTC had the shortest time from search to transplant (median, 83.5
days) versus STC (median, 85 days) or RTC (median, 93 days). In
addition, GTC searches more frequently resulted in transplants
(39%) versus STC (35%) or RTC (33%). Caucasian patients pro-
gressed to transplants nearly twice as frequently as others. Younger
patients ( 20 years), those with 75 potentially matched donors,
and those requested more than 4 donors at ﬁrst activation were
more frequently able to proceed to transplant. When the 978
potential donors were identiﬁed and requested for workup, 32.5%
were cancelled and did not proceed to transplant (11% for donor-
related reasons and 21.5% for recipient reasons). These data sug-
gest that search strategy and TC factors (ie, requesting more
donors, growing TC) lead to shorter and more successful searches.
Likelihood of transplant is less for non-Caucasian and non-His-
panic recipients. Efforts directed toward enhancing search efﬁ-
ciency may increase the chances of successful URD search and an
eventual transplant.
Percentages of Patients who Progressed from Search to Transplant
and Odds Ratio Estimates from Multivariate Logistic Regression
Factor
Percentage
Progressed
from
Search to
Transplant
Odds
Ratio 95% CI.
P-
Value
Favorable
Characteristic
Patient Race/
Ethnicity
Caucasian 39% 1.00 — —
Black/African
American 18% 0.44 (0.26, 0.74) 0.002 Caucasian
Hispanic 32% 0.57 (0.34, 0.96) 0.03
Other 21% 0.42 (0.27, 0.63) <0.0001
Patient Age
0-20 42% 1.00 — — 0–20
21-40 35% 0.65 (0.46, 0.91) 0.01
>40 21% 0.51 (0.37, 0.71) <0.0001
# 6 of 6 HLA
Matches
0-3 22% 0.49 (0.36, 0.65) <0.0001 >75
4-75 37% 1.00 — —
>75 46% 1.44 (1.11, 1.88) 0.006
# Donors at
First
Activation
1-4 32% 1.00 — — >4
>4 39% 1.35 (1.08, 1.68) 0.009
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HLA MISMATCH AND CLINICAL OUTCOME AFTER UNRELATED DONOR
(URD) NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (NST)
Ho, V.T.1,2; Kim, H.T.1; Windawi, S.1; Liney, D.1; Milford, E.2;
Cutler, C.1,2; Lee, S.J.1,2; Soiffer, R.J.1,2; Antin, J.H.1,2; Alyea, E.P.1,2
1. Dana Farber Cancer Institute, Boston, MA; 2. Brigham and Wom-
en’s Hospital, Boston, MA.
The signiﬁcance of HLA disparity in URD NST has not been
elucidated. We performed a retrospective analysis of 115 patients
who underwent URD NST from July 2000-June 2004 for hema-
tologic cancers, mainly MDS, AML, CLL, and NHL. Eighty were
matched at HLA-A, B, C, DRB1, and DQB1. Thirty were single
antigen/allele mismatched at HLA-A (n  1), HLA-B (n  1),
HLA-C (n  19), or HLA-DQ (n  9). Five were double mis-
matched: HLA-AC (n  1), HLA-BC (n  3), and HLA-
DQC (n  1). All received nonmyeloablative conditioning with
intravenous busulfex 0.8 mg/kg/d and ﬂudarabine 30 mg/m2/d 4
days. GVHD prophylaxis consisted of a calcineurin inhibitor
(CI)  prednisone or CI  mini-methotrexate based therapy. The
2 cohorts were balanced for donor and recipient age, gender
disparity, and disease status. There was a trend toward more
steroid-based GVHD prophylaxis in the mismatched group. The
stem cell source was predominantly PBSC, although 8 of 35 (23%)
mismatched patients received marrow, compared with 3 of 80 (4%)
in the matched cohort (P  .01). Median donor chimerism was
high in both mismatched and matched groups (90% and 96% at 1
month post-NST, respectively; P  .46), and this was sustained at
3 months (97% vs 96%). Grade II-IV aGVHD was signiﬁcantly
increased in the mismatched group (23/34 [68%] vs 31/80 [39%];
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P .007). This association was observed irrespective of the type of
GVHD prophylaxis given. There was no difference in chronic
GVHD (18/32 [56%] vs 43/77 [56%] in the mismatched and
matched cohorts, respectively; P  .99). Relapse rates were also
similar (49% vs 53%; P  .84). Actuarial 1-year OS was 56% for
the mismatched group and 54% for the matched cohort, with a
2-year OS of 40% and 35%, respectively (P .40). Among patients
mismatched at HLA-C, aGVHD incidence was 16/23 (70%), and
there was a signiﬁcant trend toward decreased 1 and 2-year survival
(45% and 22%, vs 60% and 44% in C-matched patients; P  .07).
There was no difference in relapse associated with HLA-C dispar-
ity. In Cox regression-adjusted for HLA-disparity, donor/recipient
age, gender disparity, stem cell source (BM vs PBSC), disease
status, and GVHD prophylaxis, there remained a trend toward
worse survival for patients mismatched at HLA-C (HR 2.1; P 
.09), and grade II-IV acute GVHD was the only statistically sig-
niﬁcant predictor of death (HR 4.7; P  .001). We conclude that
single antigen/allele mismatch in HLA-A, B, and DQ is permissi-
ble for URD NST, but HLA-C disparity should be treated with
caution.
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CONTRIBUTIONS OF KIR GENOTYPE AND HLA-C-ENCODED KIR LI-
GANDS TO THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Fischer, J.1; Ottinger, H.D.2; Ferencik, S.2; Schwan, M.A.1; Middleton,
P.G.3; Grosse-Wilde, H.2; Wernet, P.1; Dickinson, A.M.3; Uhrberg,
M.1 1. Institute for Transplantation Diagnostics and Cell Therapeutics,
Du¨sseldorf University, Du¨sseldorf, Germany; 2. Institute of Immunol-
ogy, University Hospital of Essen, Essen, Germany; 3. Department of
Haematology, School of Clinical and Laboratory Sciences, University of
Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
A hallmark of human natural killer cells is the expression of
killer-cell immunoglobulin-like receptors (KIR), which enable the
detection of changes in HLA class I expression. The KIR family is
highly polymorphic and characterized by interindividual dif-
ferences in the number of inherited genes, which vary from 7
to sometimes 14 different genes. The aim of this study was
to analyze the inﬂuence of KIR genes and HLA-encoded li-
gands on allogeneic SCT outcome. Statistical analyses of trans-
plantation outcomes in unrelated HLA-matched transplanta-
tion for chronic myeloid leukemia (CML; n  109) by
univariate and multivariate analyses exhibited a signiﬁcant inﬂu-
ence of HLA-C-encoded KIR epitopes on overall survival.
Whereas patients with 2 HLA-Casn80 allotypes (HLA-C group
1) had an overall survival (OS) at 6 years of 76%, patients with 1
or 2 HLA-Clys80 allotypes (HLA-C group 2) exhibited a sig-
niﬁcantly decreased OS of 54% (independent of transplant
source and disease status in logistic regression analysis). Among
the latter subgroup, those patients, who received a transplant from
a donor with 2 HLA-Clys80 allotypes had a substantially better
event-free survival (EFS  79%) than those who received a trans-
plant from a donor with 1 or 2 HLA-Casn80 allotypes (EFS 
40%). Next, generic typing for presence or absence of KIR genes
was employed to assess the contribution of KIR genotype on SCT
outcome. A subgroup of patients was deﬁned who received grafts
from donors with 1 additional stimulatory KIR gene compared to
the patient’s genotype (KIRS_D1). A beneﬁcial inﬂuence of the
KIRS_D1 constellation on OS was seen in the unrelated SCT
study described earlier, as well as in a related SCT study of
HLA-identical sibling donor transplantations (n  65). Moreover,
epistatic interaction was seen between KIR genes and HLA-C
epitopes; among the patients with 1 or 2 HLA-Clys80 allotypes,
the KIRS_D1 group performed signiﬁcantly better (OS  83%)
than the remaining patients (OS  47%). In summary, consider-
ation of donor/patient KIR genotypes in combination with patient-
encoded KIR ligands might lead to an improvement in donor
selection in SCT.
IMMUNE RECONSTITUTION
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THE GENERATION OF DONOR-DERIVED VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS AND ADENO-
VIRUS ANTIGENS FOR CLINICAL USE
Bollard, C.M.; Leen, A.; Huls, H.; Myers, G.D.; Sili, U.; Rooney, C.M.;
Helsop, H.E. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX.
Cytomegalovirus (CMV) and adenovirus are major viral patho-
gens causing morbidity and mortality in immunocompromised
patients undergoing allogeneic stem cell transplantation. Previous
studies have shown that prophylactic adoptive immunotherapy
with donor-derived cytotoxic T lymphocytes (CTLs) directed
against Epstein-Barr virus (EBV) and CMV can effectively prevent
the clinical manifestations of these viruses. We have extended these
studies by generating CTLs from normal donor PBMCs that
should restore cellular immunity to both CMV and adenovirus
simultaneously. We have generated a clinical grade recombinant
adenovirus type 5 vector pseudotyped with a type 35 ﬁber
(Ad5f35pp65) carrying a transgene for the immunodominant CMV
antigen, pp65. We have developed a protocol using an initial round
of stimulation with autologous mononuclear cells transduced with
Ad5f35pp65, followed by 2 rounds of weekly stimulation with
autologous EBV-transformed lymphoblastoid cell lines (LCLs)
transduced with the same vector using MOIs of 10 and 100,
respectively. After 3 rounds of stimulation, 3 CTL cultures con-
tained a mean of 86% (range, 82%-95%) CD8ve and a mean of
9.5% (range, 5%-14%) CD4ve cells. Evaluable CTL lines
showed signiﬁcant cytotoxicity in chromium release assays against
autologous ﬁbroblasts and LCL infected with a CMV vector and
LCL infected with the Ad5GFP vector. The observed cytotoxicity
was speciﬁc because nontransduced LCLs, transduced and non-
transduced MHC-mismatched LCLs, and autologous PHA blasts
were not killed. ELISPOT assays on CTL demonstrated a mean of
459 (range, 284–634) and 497.5 (range, 402–593) numbers of cells
secreting interferon-gamma after stimulation with autologous
PBMC stimulated with CMV and adenovirus peptides, respec-
tively. Using MHC-peptide tetramers in a HLA-A2/B7ve donor
we have been able to demonstrate the simultaneous presence of
CD8ve cells recognizing peptide epitopes from CMV pp65
(range, 2.41%-9.08%) and adenovirus hexon (1.69%) in the CTL
culture. In summary, we have developed a protocol for the efﬁcient
generation ex vivo of CTL with virus speciﬁcity for CMV and
adenovirus. We are currently growing these CTL lines for clinical
use in a FDA-approved protocol to restore cellular immunity to
these viruses after allogeneic stem cell transplantation.
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ASPERGILLUS FUMIGATUS-SPECIFIC CYTOTOXIC T-CELL LINES GEN-
ERATED THROUGH USE OF ASP F16 PROTEIN-SPANNING POOLS OF
OVERLAPPING PENTADECAPEPTIDES
Ramadan, G.1; Davies, B.1; Kurup, V.P.2; Keever-Taylor, C.A.1 1.
Medical College of Wisconsin, Milwaukee, WI; 2. VA Medical Center,
Milwaukee, WI.
Invasive aspergillosis (IA) fungal infection is often lethal in im-
munosuppressed individuals, particularly patients undergoing
blood or marrow transplantation. Although ﬁrst-line defense
against IA is largely mediated by neutrophils and macrophages,
there is evidence that Th1 type T-cell response is essential in the
control of infection. We prepared 104 overlapping pentadecapep-
tides (11-aa overlap with previous peptide) spanning the coding
region of the aspergillus allergen, Asp f16, previously shown to
induce Th1-type cell responses in mice. These were used to prime
T-cell responses in healthy donors. PBMC from 5/5 donors pro-
liferated strongly to complete peptide pool (PPC)-pulsed autolo-
gous monocyte-derived dendritic cells (DC) generated by 2–3 days
of culture with GM-CSF and IL-4, pulsed, then matured for 2 days
with a cocktail of inﬂammatory cytokines. Cytotoxic T lymphocyte
(CTL) lines were generated from 2 donors by weekly priming of
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